Speaker
Description
Pseudoprogression is a confounding treatment response pattern characterized by apparent disease progression followed by eventual treatment response. Patients who eventually experience clinical benefit may be incorrectly classified as progressors by RECIST criteria, leading to premature cessation of treatment. The exact mechanism of pseudoprogression is not fully understood and existing mathematical models of treatment response often are unable to exhibit dynamics of pseudoprogression. We develop a novel mechanistic ODE model of tumor-immune dynamics and ctDNA shedding and in response to immune checkpoint inhibitor treatment that is capable of naturally exhibiting pseudoprogression. We then demonstrate how ctDNA dynamics may be able to distinguish pseudoprogressors from true progressors.
